A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Centocor; Janssen Research & Development
- 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 21 Aug 2013 Planned end date (Nov 2015) added as reported by ClinicalTrials.gov.
- 24 Sep 2009 New trial record.